Results 251 to 260 of about 96,820 (286)
Some of the next articles are maybe not open access.
Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors
2010Testosterone gets converted into the more potent 5-[alpha]-dihydrotestosterone by 5-[alpha]- reductase. dihydrotestosterone (DHT) controls prostate mitotic activity and potentially prostate carcinogenesis. Interventions that inhibit 5-[alpha]-reductase have potential as preventive agents for prostate cancer.
openaire +2 more sources
Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review
Sexual Medicine Reviews, 20135α-reductase inhibitors (5ARI) include finasteride and dutasteride, and are commonly prescribed in the treatment of benign prostatic hyperplasia and androgenic alopecia. 5ARIs are associated with several known adverse effects (AEs), with varying reported prevalence rates.The aim was to review and summarize findings from published literature detailing ...
Landon, Trost +2 more
openaire +2 more sources
The role of 5-alpha-reductase inhibitors in active surveillance
Current Opinion in Urology, 2012Active surveillance is now considered one of the preferred treatments for men with favorable risk prostate cancer (PCa). Unfortunately, 30-50% of men choosing active surveillance will progress and require therapy. In this context, we will present recent data on the efficacy of 5-alpha-reductase inhibitors (5-ARIs) in secondary prevention among men with
David, Margel, Neil, Fleshner
openaire +2 more sources
5-Alpha Reductase Inhibitors in Prostate Cancer
2010Androgenic effects in prostate cancer cells depend on the synthesis and metabolism of hormones and the presence of androgen receptor. 5-alpha reductase isoenzymes I and II differ in chromosomal localization, pH optimum, enzyme kinetics, and expression in benign and malignant prostate tissue.
openaire +1 more source
Finasteride: a 5 alpha-reductase inhibitor.
Clinical pharmacy, 1993The pharmacology and pharmacokinetics of finasteride are reviewed, and finasteride's clinical efficacy, adverse effects, and dosage in patients with benign prostatic hyperplasia (BPH) are described. Finasteride is a member of a new class of medications, the azasteroids, that have antiandrogenic activity limited to certain tissues, including the ...
openaire +1 more source
Long-Term Experience with 5-alpha-Reductase Inhibitors.
Reviews in urology, 2011Finasteride, a 5-alpha-reductase inhibitor, dramatically suppresses the production of dihydrotestosterone in men; thus, attention has turned to this agent for the treatment of benign prostatic hyperplasia (BPH). A number of randomized clinical trials have studied finasteride's effects on prostate size, BPH symptoms, flow rate, and prostate-specific ...
openaire +2 more sources
[5-alpha-reductase inhibitors in benign prostatic hyperplasia].
Khirurgiia, 1997Sixteen patients presenting benign prostate gland hyperplasia undergo conservative treatment with Finasterid over the period 1992 through 1995. Prior to treatment, in all patients the subjective complaints are assayed on the basis of the IPSS rating system for severity of complaints.
P, Panchev, K, Neĭkov
openaire +1 more source
5 alpha-reductase inhibitors and prostatic disease.
Clinical endocrinology, 19945 alpha-Reductase inhibitors are a new class of substances with very specific effects on type I and type II 5 alpha R which may be of use in the treatment of skin disease, such as male pattern baldness, male acne and hirsutism, as well as prostatic hyperplasia and prostate cancer.
openaire +1 more source
[5-alpha reductase inhibitors and prostate cancer prevention].
Zhonghua nan ke xue = National journal of andrology, 20135-alpha reductase inhibitors decrease the level of dihydrotestosterone (DHT) by inhibiting 5-alpha reductase. Trials on 5-alpha reductase inhibitors in prostate cancer prevention showed that they could significantly decrease the incidence of prostate cancer, but meanwhile increase high-grade cases as well.
openaire +1 more source